HEALTH● LOW1h ago · Oct 19, 2026, 6:31 PM
Zentalis rises as lead asset extends survival in mid-stage trial for ovarian cancer
Seeking Alpha Tech · global
Zentalis' lead asset showed extended survival in a mid-stage clinical trial for ovarian cancer, leading to an increase for the company. This represents a significant development in cancer treatment research.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH56m agoFake Drug Allegations: NAFDAC investigates death of NYSC memberPremium TimesHEALTH1h agoPsychology experts agree: "Those with dirty and messy cars suffer from low self-esteem"ClarínHEALTH2h agoPsychology says that some people reach old age and continue to seek activities that arouse their interest. They learn new skills, participate in social gatherings or dedicate time to personal projects. Although they recognize the changes associated with age, they do not organize their whole lifeClarínHEALTH2h agoTrump launches women's health division within NIH alongside Melania TrumpCBS News